您当前位置: 首页  研究生培养  招生  研究生导师

张章

发布时间:2017-06-02 发布单位:药学院

张章,男,博士,副教授,硕士生导师。2003年毕业于安徽中医学院获医学学士学位,2006年于暨南大学获药理学硕士学位,2016年于暨南大学获医学博士学位。先后在广州市朗圣药业有限公司、中国科学院广州生物医药与健康研究院从事肿瘤药物开发及机制研究。20172月加入暨南大学药学院工作。

主持暨南大学校级启动基金1项,横向课题3项,参与国家、省、市级课题10项;申请中国发明专利12项(其中已授权8项)、PCT专利3项;在Cancer LettersJournal of Medicinal ChemistryBioorganic & Medicinal Chemistry LettersSCI期刊发表SCI论文28篇,其中第一/共一作者论文9篇。曾获广东省科技进步二等奖2016年),广州市科技进步一等奖2015年),中国科学院第四届青年创业大赛金奖2011年)等荣誉。部分科研项目已经产业转化,其中1.1类新药耐克替尼(GZD824),已经完成I期临床试验,正准备进入II期临床研究阶段。

 

主要研究方向:

小分子靶向抗肿瘤药物的筛选及临床前评价;

抗肿瘤候选分子的药效及其作用机制研究;

肿瘤耐药机制及克服耐药的新方法研究。

代表性论文:

1. Qiuju Xun #, Zhang Zhang #, Jinfeng Luo, Linjiang Tong, Jian Zou, Yong Xu, Hua Xie, Xiaoyun Lu*, Ke Ding*. Structure-Based Design of 2-Oxo-3, 4-dihydropyrimido [4, 5-d] Pyrimidines as Novel Colony Stimulating Factor-1 Receptor (CSF1R) Kinase Inhibitors. Journal of Medicinal Chemistry. 2018, doi: 10.1021/acs.jmedchem.7b01612. (Co-first, IF=6.259)

2. Zhang Zhang, Ren Xiaomei, Lu Xiaoyun, Wang Deping, Hu Xianjing, Zheng Yi, Song Liyan ,Pang Hongwen,Yu Rongmin*,Ding Ke*, GZD856, a novel potent PDGFRα/β inhibitor, suppresses the growth and migration of lung cancer cells in vitro and in vivo. Cancer letters, 2016, 375:172-178 (First author, IF=6.375)

3. Li Tan#, Zhang Zhang#, Donglin Gao, Jinfeng Luo, Zhenchao Tu, Zhengqiu Li, Lijie Peng,Xiaomei Ren,*and Ke Ding*, 4-Oxo-1, 4-Dihydroquinoline-3-Carboxamide Derivatives as Selective Axl Kinase Inhibitors, Journal of Medicinal Chemistry.2016, 59(14):6807-25Co-firstIF=5.889);

4. Xiaomei Ren#, Xiaofen Pan#, Zhang Zhang#, Deping Wang, Xiaoyun Lu, Yang Bai, Donghai Wen, Huoyou Long, Jinfeng Luo, Yubing Feng, Xiaoxi Zhuang, Fengxiang Zhang, Jianqi Liu, Fang Leng, Xingfen Lang, Zhengchao Tu, Jinxuan Pan and Ke Ding*.Identification of GZD824 as an orally bioavailable Bcr-Abl inhibitor overcoming the clinically acquired gene mutation induced resistance against imatinib. Journal of Medicinal Chemistry. 2013, 56, 879-894Co-first, IF=5.889);

5. Zhang Zhang #, Jian Zou #, Lei Yu#, Jinfeng Luo , Yan Li , Zhengchao Tu , Xiaomei Ren , Hongcheng Wei*, Liyan Song *,Xiaoyun Lu * and Ke Ding *. Y L143, a novel mutant-selective irreversible EGFR inhibitor, overcomes EGFRL858R/T790M mutant resistance in vitro and in vivo. Cancer Medicine. 2018,10.1002/cam4.1392Co-firstIF=3.36

6. Xiaoyun Lu#, Zhang Zhang#, Xiaomei Ren, Deping Wang, Xiaoxi Zhuang, Ke Ding. Synthesis and Identification of GZD856 as an orally bioavailable Bcr-AblT315I inhibitor overcoming acquired imatinib resistance. Journal Of Enzyme Inhibition And Medicinal Chemistry, 2017, 32(1):331-336. (Co-first, IF= 3.428)

7. Xiaoyun Lu#, Zhang Zhang#, Weihua Li , Xiaomei Ren , Xiaofeng Pan , Huoyou long , Deping Wang , Lianwen zhang , Xiaoxi Zhuang, Jingfeng Luo, Rongmin Yu, Ke Ding*.Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl T315I mutant. Bioorganic & Medicinal Chemistry Letters.2015,17:3458-63 (Co-first, IF= 2.486)

8. Shen Jiayi#, Li Xiaokai#, Zhang Zhang#, Luo Jinfeng, Long Huoyou, Tu Zhengchao, Zhou Xiaoping, Ding Ke, Lu Xiaoyun. 3-aminopyrazolopyrazine derivatives as spleen tyrosine kinase inhibitors. Chemical Biology & Drug Design, 2016, 88(5):690-698.  (Co-first, IF= 2.802)

9. Yupeng Li#, Mengjie Shen#, Zhang Zhang, Jinfeng Luo, Xiaofen Pan, Xiaoyun Lu, Huoyou Long, Donghai Wen, Fengxiang Zhang, Fang Leng, Yingjun Li, Zhengchao Tu, Xiaomei Ren, and Ke Ding*.Design, Synthesis, and Biological Evaluation of 3-(1H-1,2,3-Triazol-1-yl)benzamide Derivatives as Potent Pan Bcr-Abl Inhibitors Including the Threonine315→Isoleucine315 Mutant. Journal of Medicinal Chemistry, 2012, 55, 10033–10046 (IF=5.889)

10. Cheng Mo, Zhang Zhang, Christopher P. Guise, Xueqiang Li, Jinfeng Luo, Zhengchao Tu, Yong Xu, Adam V. Patterson, Jeff B. Smaill*, Xiaomei Ren*, Xiaoyun Lu*, and Ke Ding*.2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors. ACS Medicinal Chemistry Letters.2017.DOI: 10.1021/acsmedchemlett.7b00091(IF=3.355)

 

 

代表性发明专利:

1. 丁克,耿美玉,谈理,丁健,张章,艾菁,任小梅,高冬林,涂正超,陆小云,张冬梅,取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用:中国发明专利,申请号201510509618.5. 2015-8-19

2. 丁克,耿美玉,谈理,丁健,张章,艾菁,任小梅,高冬林,涂正超,陆小云,张冬梅,取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用:PCT专利,申请号PCT/CN2016/095813. 2016-8-18

3. 丁克、王德平、裴端卿、潘景轩、张章、冯玉冰、罗坤、甘继荣、庄晓曦、段磊;吡啶基噻唑胺类化合物及其应用;专利号:ZL 200910193571.0;授权时间:2011.12.26已转化,完成I期临床研究);

4. 丁克、王德平、裴端卿、张章、沈梦婕、罗坤、冯玉冰;杂环炔苯类化合物及其药用组合物和应用;专利号ZL 201010216603.7;授权时间:2013.07.24已转化,完成I期临床研究);

5. 丁克、王德平、裴端卿、张章、沈梦婕、罗坤、冯玉冰;杂环炔苯类化合物及其药用组合物和应用;国际专利PCT申请,优先权号:CN 201010216603.7申请号:PCT/CN2011/000935,国际公布号:WO 2012/000304已转化,完成I期临床研究)。

奖励及荣誉:

2011年:中科院第四届青年创业大赛金奖(团队)

2011年:中国科学院广州生物医药与健康研究院先进科技工作者(个人);

2015年:广州市科技进步一等奖(团队)

2016年:广东省科技进步二等奖(团队)

联系方式:

zhang_zhang@jnu.edu.cn